<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107925</url>
  </required_header>
  <id_info>
    <org_study_id>12921</org_study_id>
    <secondary_id>H7T-MC-TADI</secondary_id>
    <nct_id>NCT01107925</nct_id>
  </id_info>
  <brief_title>Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease</brief_title>
  <acronym>FEATHER</acronym>
  <official_title>A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight Aspirin-Treated Subjects With Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 5-milligram (mg) dose of prasugrel in low body weight (LBW) patients with coronary artery
      disease produces a pharmacodynamic response within the same therapeutic range as 10-mg dose
      in higher body weight (HBW) patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Maximum Platelet Aggregation (MPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12 (Period 1)</measure>
    <time_frame>Baseline, Day 12</time_frame>
    <description>MPA to 20 micromolar (μM) ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA reflects stronger platelet inhibition, whereas a higher MPA reflects weaker inhibition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vasodilator-Associated Stimulated Phosphoprotein (VASP) at Day 12 of Therapy</measure>
    <time_frame>Baseline, Day 12</time_frame>
    <description>VASP phosphorylation levels, expressed as the platelet reactivity index (PRI), reflect the degree of thienopyridine-mediated P2Y12 receptor inhibition and were used to compare prasugrel versus clopidogrel, in low body weight (LBW) participants compared to higher body weight (HBW) participants. PRI was calculated by VASP. The PRI indicates the level of P2Y12 receptor inhibition. A lower PRI reflects stronger inhibition of P2Y12 receptor thus stronger platelet inhibition, whereas a higher PRI reflects weaker inhibition of P2Y12 receptor and weaker platelet inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in VerifyNow® P2Y12 Reaction Units (PRU) at Day 12 of Therapy</measure>
    <time_frame>Baseline, Day 12</time_frame>
    <description>The Accumetrics VerifyNow® P2Y12 assay measures platelet aggregation in whole blood and is reported in PRU. PRU indicates the extent of P2Y12 receptor-mediated platelet aggregation calculated as a function of rate and extent of platelet aggregation in an adenosine phosphate (ADP)-containing channel of the device. A lower PRU reflects stronger inhibition of platelet aggregation, whereas a higher PRU reflects weaker inhibition of platelet aggregation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Analysis of the Concentration-Time Curve (AUC)</measure>
    <time_frame>baseline (pre-dose) up to 4 hours post-dose</time_frame>
    <description>A pharmacokinetic-pharmacodynamic (PK-PD) analysis comparing MPA (LTA) and AUC was conducted as originally intended, however the graphic output is not possible here. Therefore, the PK portion is presented here as AUC and the PD portion is presented in Secondary Outcome Measure #5. AUC was calculated through the last scheduled sampling time of 4 hours [AUC (0-4)] or through the sampling time of the last quantifiable concentration prior to 4 hours. AUC values were denoted AUC(0-tlast) in both instances.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Maximum Platelet Aggregation (MPA) as Measured by Light Transmission Aggregometry (LTA) at Day 12 of Therapy</measure>
    <time_frame>Baseline , Day 12</time_frame>
    <description>MPA to 20 micromolar (μM) adenosine diphosphate (ADP) was assessed by LTA, an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA reflects stronger platelet inhibition, whereas a higher MPA reflects weaker inhibition.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>5 mg prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>75 mg clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>Administered orally, daily for 12 days</description>
    <arm_group_label>5 mg prasugrel</arm_group_label>
    <arm_group_label>10 mg prasugrel</arm_group_label>
    <other_name>Efient</other_name>
    <other_name>Effient</other_name>
    <other_name>LY640315</other_name>
    <other_name>CS747</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Administered orally, daily for 12 days</description>
    <arm_group_label>75 mg clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a history of stable coronary artery disease who are not currently
             indicated for treatment with a thienopyridine (that is, prasugrel, clopidogrel, or
             ticlopidine)

          -  Provision of written informed consent

          -  For women of child-bearing potential only (that is, women who are not surgically or
             chemically sterilised and who are between menarche and 1 year post menopause), test
             negative for pregnancy (based on a urine or serum pregnancy test to be performed
             before randomisation) and agree to use a reliable method of birth control during the
             study

        Exclusion Criteria:

          -  Unstable coronary artery disease

          -  Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery
             (CABG) within the previous 90 days

          -  History of refractory ventricular arrhythmias within the last 6 months; an implanted
             defibrillator device; congestive heart failure within 6 months prior to screening;
             major surgery, or severe trauma, fracture or organ biopsy within 3 months prior to
             enrollment

          -  Any planned surgical procedure or any coronary revascularisation (surgical or
             percutaneous) planned within 60 days following randomisation

          -  Any known contraindication to treatment with an antiplatelet agent

          -  Significant hypertension at the time of screening or randomisation

          -  Clinically significant out-of-range values for platelet count or haemoglobin at
             screening, in the investigator's opinion, or results of clinical laboratory tests at
             the time of screening that are judged to be clinically significant for the study
             population, as determined by the investigator

          -  Prior history or presence of significant bleeding disorders, abnormal bleeding
             tendency, or personal history of coagulation or bleeding disorders.

          -  Prior history or clinical suspicion of cerebral vascular malformations, intracranial
             neoplasm, Transient Ischemic Attack (TIA) or stroke.

          -  Prior history of thrombocytopenia or thrombocytosis

          -  Use of antiplatelet agents (besides aspirin) within 10 days prior to screening; the
             use (or planned use) of heparin, oral anticoagulants, or fibrinolytic agents within 30
             days of screening; or subjects receiving daily treatment with nonsteroidal
             anti-inflammatory drugs (NSAIDS) or cyclooxygenase-2 (COX-2) inhibitors that cannot be
             discontinued for the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <results_first_submitted>July 27, 2012</results_first_submitted>
  <results_first_submitted_qc>July 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2012</results_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>5 mg Prasugrel (LBW)</title>
          <description>During Study Period 1, participants received the 5-milligram (mg) prasugrel dose for 12 days without intervening or terminal washout periods. Participants in the low body weight (LBW; &lt;60 kilograms [kg]) treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2.</description>
        </group>
        <group group_id="P2">
          <title>10 mg Prasugrel (LBW)</title>
          <description>Participants in the LBW treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
        </group>
        <group group_id="P3">
          <title>75 mg Clopidogrel (LBW)</title>
          <description>Participants in the LBW treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 75-mg clopidogrel or 10-mg prasugrel dose during Study Period 2 or Study Period 3.</description>
        </group>
        <group group_id="P4">
          <title>5 mg Prasugrel (HBW)</title>
          <description>Participants in the higher body weight (HBW; ≥ 60 kg) treatment sequence in Study Period 1 (10 mg prasugrel) were switched to either the 5-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
        </group>
        <group group_id="P5">
          <title>10 mg Prasugrel (HBW)</title>
          <description>During Study Period 1, participants in the HBW treatment sequence received the 10-mg prasugrel dose for 12 days without intervening or terminal washout periods.</description>
        </group>
        <group group_id="P6">
          <title>75 mg Clopidogrel (HBW)</title>
          <description>Participants in the HBW treatment sequence in Study Period 1 (10 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1-Randomization up Through Day 12</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Took at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="37"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">5 mg prasugrel (Period 1, LBW treatment) switched to 10 mg prasugrel or 75 mg clopidogrel (Period 2)</participants>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="0">10 mg prasugrel (Period 1, HBW treatment) switched to 5 mg prasugrel or 75 mg clopidogrel (Period 2)</participants>
                <participants group_id="P6" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Took at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="17">75 mg clopidogrel (Period 2, LBW treatment sequence) crossed over to 10 mg prasugrel (Period 3).</participants>
                <participants group_id="P3" count="15">10 mg prasugrel (Period 2, LBW treatment sequence) crossed over to 75 mg clopidogrel (Period 3).</participants>
                <participants group_id="P4" count="16">75 mg clopidogrel (Period 2, HBW treatment sequence) crossed over to 5 mg prasugrel (Period 3).</participants>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="20">5 mg prasugrel (Period 2, HBW treatment sequence) crossed over to 75 mg clopidogrel (Period 3).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Took at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose Sequence: Pras 5mg, Pras 10mg, Clop 75mg (LBW)</title>
          <description>Participants in the low body weight (LBW; &lt;60 kilograms [kg]) group received 5 milligrams (mg) of Prasugrel (Pras) during Study Period 1, followed by 10 mg Pras in Study Period 2, followed by 75 mg clopidogrel (Clop) in Study Period 3.</description>
        </group>
        <group group_id="B2">
          <title>Dose Sequence: Pras 5mg, Clop 75 mg, Pras 10mg (LBW)</title>
          <description>Participants in the LBW group received 5 mg Pras during Study Period 1, followed by 75 mg Clop in Study Period 2, and 10 mg Pras in Study Period 3.</description>
        </group>
        <group group_id="B3">
          <title>Dose Sequence: Pras 10mg, Pras 5mg, Clop 75 mg (HBW)</title>
          <description>Participants in the higher body weight (HBW; ≥60 kg) group received 10 mg Pras during Study Period 1, followed by 5 mg Pras in Study Period 2, followed by 75 mg Clop in Study Period 3.</description>
        </group>
        <group group_id="B4">
          <title>Dose Sequence: Pras 10mg, Clop 75 mg, Pras 5mg (HBW)</title>
          <description>Participants in the HBW group received 10 mg Pras during Study Period 1, followed by 5 mg Pras in Study Period 2, followed by 75 mg Clop in Study Period 3.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="8.07"/>
                    <measurement group_id="B2" value="63.2" spread="7.65"/>
                    <measurement group_id="B3" value="61.4" spread="9.57"/>
                    <measurement group_id="B4" value="64.6" spread="6.91"/>
                    <measurement group_id="B5" value="62.6" spread="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.06" spread="4.575"/>
                    <measurement group_id="B2" value="56.78" spread="2.619"/>
                    <measurement group_id="B3" value="83.60" spread="17.146"/>
                    <measurement group_id="B4" value="85.96" spread="11.898"/>
                    <measurement group_id="B5" value="71.33" spread="17.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tobacco Use Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Tobacco Use Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tobacco Use No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Maximum Platelet Aggregation (MPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12 (Period 1)</title>
        <description>MPA to 20 micromolar (μM) ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA reflects stronger platelet inhibition, whereas a higher MPA reflects weaker inhibition.</description>
        <time_frame>Baseline, Day 12</time_frame>
        <population>Primary intent-to-treat (ITT) pharmacodynamic (PD) population: all randomized participants who continued in the study through Day 12, and had at least 1 evaluable PD assessment at Day 12. Participants were analyzed based on the treatment group they were randomized to irrespective to the treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 5 mg (LBW)</title>
            <description>Participants in the low body weight (LBW; &lt;60 kilograms [kg]) group received the 5-milligram (mg) prasugrel dose in Study Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 10 mg (HBW)</title>
            <description>Participants in the higher body weight (HBW; ≥60 kg) group received the 10-mg prasugrel dose in Study Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maximum Platelet Aggregation (MPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12 (Period 1)</title>
          <description>MPA to 20 micromolar (μM) ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA reflects stronger platelet inhibition, whereas a higher MPA reflects weaker inhibition.</description>
          <population>Primary intent-to-treat (ITT) pharmacodynamic (PD) population: all randomized participants who continued in the study through Day 12, and had at least 1 evaluable PD assessment at Day 12. Participants were analyzed based on the treatment group they were randomized to irrespective to the treatment they received.</population>
          <units>percent aggregation</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00" lower_limit="70.00" upper_limit="80.00"/>
                    <measurement group_id="O2" value="76.40" lower_limit="71.00" upper_limit="84.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12 (n=32, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.00" lower_limit="37.70" upper_limit="56.45"/>
                    <measurement group_id="O2" value="47.00" lower_limit="39.00" upper_limit="57.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Difference in median MPA in response to 20 μM ADP in LBW participants who received 5 mg prasugrel to the 75th percentile of MPA response to 20 μM ADP in HBW participants who received10 mg prasugrel at the end of Study Period 1 (Baseline through Day 12) was estimated from the observed data.</non_inferiority_desc>
            <p_value>0.526</p_value>
            <method>bootstrap (to determine 95% CI)</method>
            <param_type>Estimate of the difference</param_type>
            <param_value>-10.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.40</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
            <estimate_desc>Estimate of the difference = [median (low body weight) - Q3 (higher body weight)]</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vasodilator-Associated Stimulated Phosphoprotein (VASP) at Day 12 of Therapy</title>
        <description>VASP phosphorylation levels, expressed as the platelet reactivity index (PRI), reflect the degree of thienopyridine-mediated P2Y12 receptor inhibition and were used to compare prasugrel versus clopidogrel, in low body weight (LBW) participants compared to higher body weight (HBW) participants. PRI was calculated by VASP. The PRI indicates the level of P2Y12 receptor inhibition. A lower PRI reflects stronger inhibition of P2Y12 receptor thus stronger platelet inhibition, whereas a higher PRI reflects weaker inhibition of P2Y12 receptor and weaker platelet inhibition.</description>
        <time_frame>Baseline, Day 12</time_frame>
        <population>As-treated pharmacodynamic (PD) population: all randomized participants who received at least 1 dose of study drug and provided at least 1 evaluable PD measure at 1 of the 3 periods. Participants were analyzed based on the treatment they received for each period regardless of their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Prasugrel (LBW)</title>
            <description>During Study Period 1, participants received the 5-milligram (mg) prasugrel dose for 12 days without intervening or terminal washout periods. Participants in the low body weight (LBW; &lt;60 kilograms [kg]) treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2.</description>
          </group>
          <group group_id="O2">
            <title>10 mg Prasugrel (LBW)</title>
            <description>Participants in the LBW treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
          </group>
          <group group_id="O3">
            <title>75 mg Clopidogrel (LBW)</title>
            <description>Participants in the LBW treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 75-mg clopidogrel or 10-mg prasugrel dose during Study Period 2 or Study Period 3.</description>
          </group>
          <group group_id="O4">
            <title>5 mg Prasugrel (HBW)</title>
            <description>Participants in the higher body weight (HBW; ≥ 60 kg) treatment sequence in Study Period 1 (10 mg prasugrel) were switched to either the 5-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
          </group>
          <group group_id="O5">
            <title>10 mg Prasugrel (HBW)</title>
            <description>During Study Period 1, participants in the HBW treatment sequence received the 10-mg prasugrel dose for 12 days without intervening or terminal washout periods.</description>
          </group>
          <group group_id="O6">
            <title>75 mg Clopidogrel (HBW)</title>
            <description>Participants in the HBW treatment sequence in Study Period 1 (10 mg prasugrel) were switched to either the 75-mg clopidogrel or 5-mg prasugrel dose either during Study Period 2 or Study Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vasodilator-Associated Stimulated Phosphoprotein (VASP) at Day 12 of Therapy</title>
          <description>VASP phosphorylation levels, expressed as the platelet reactivity index (PRI), reflect the degree of thienopyridine-mediated P2Y12 receptor inhibition and were used to compare prasugrel versus clopidogrel, in low body weight (LBW) participants compared to higher body weight (HBW) participants. PRI was calculated by VASP. The PRI indicates the level of P2Y12 receptor inhibition. A lower PRI reflects stronger inhibition of P2Y12 receptor thus stronger platelet inhibition, whereas a higher PRI reflects weaker inhibition of P2Y12 receptor and weaker platelet inhibition.</description>
          <population>As-treated pharmacodynamic (PD) population: all randomized participants who received at least 1 dose of study drug and provided at least 1 evaluable PD measure at 1 of the 3 periods. Participants were analyzed based on the treatment they received for each period regardless of their randomized treatment assignment.</population>
          <units>percentage PRI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.57" spread="4.44"/>
                    <measurement group_id="O2" value="86.44" spread="4.45"/>
                    <measurement group_id="O3" value="86.44" spread="4.45"/>
                    <measurement group_id="O4" value="86.77" spread="3.42"/>
                    <measurement group_id="O5" value="86.76" spread="3.37"/>
                    <measurement group_id="O6" value="86.77" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12 (n=32,31,30,32,36,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.54" spread="15.77"/>
                    <measurement group_id="O2" value="15.09" spread="11.71"/>
                    <measurement group_id="O3" value="39.01" spread="17.49"/>
                    <measurement group_id="O4" value="56.87" spread="15.47"/>
                    <measurement group_id="O5" value="27.79" spread="18.13"/>
                    <measurement group_id="O6" value="56.35" spread="18.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in VerifyNow® P2Y12 Reaction Units (PRU) at Day 12 of Therapy</title>
        <description>The Accumetrics VerifyNow® P2Y12 assay measures platelet aggregation in whole blood and is reported in PRU. PRU indicates the extent of P2Y12 receptor-mediated platelet aggregation calculated as a function of rate and extent of platelet aggregation in an adenosine phosphate (ADP)-containing channel of the device. A lower PRU reflects stronger inhibition of platelet aggregation, whereas a higher PRU reflects weaker inhibition of platelet aggregation.</description>
        <time_frame>Baseline, Day 12</time_frame>
        <population>As-treated pharmacodynamic (PD) population: all randomized participants who received at least 1 dose of study drug and provided at least 1 evaluable PD measure at 1 of the 3 periods. Participants were analyzed based on the treatment they received for each period regardless of their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Prasugrel (LBW)</title>
            <description>During Study Period 1, participants received the 5-milligram (mg) prasugrel dose for 12 days without intervening or terminal washout periods. Participants in the low body weight (LBW; (&lt;60 kilograms [kg]) treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2.</description>
          </group>
          <group group_id="O2">
            <title>10 mg Prasugrel (LBW)</title>
            <description>Participants in the LBW treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
          </group>
          <group group_id="O3">
            <title>75 mg Clopidogrel (LBW)</title>
            <description>Participants in the LBW treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 75-mg clopidogrel or 10-mg prasugrel dose during Study Period 2 or Study Period 3.</description>
          </group>
          <group group_id="O4">
            <title>5 mg Prasugrel (HBW)</title>
            <description>Participants in the higher body weight (HBW; ≥ 60 kg) treatment sequence in Study Period 1 (10 mg prasugrel) were switched to either the 5-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
          </group>
          <group group_id="O5">
            <title>10 mg Prasugrel (HBW)</title>
            <description>During Study Period 1, participants in the HBW treatment sequence received the 10-mg prasugrel dose for 12 days without intervening or terminal washout periods.</description>
          </group>
          <group group_id="O6">
            <title>75 mg Clopidogrel (HBW)</title>
            <description>Participants in the HBW treatment sequence in Study Period 1 (10 mg prasugrel) were switched to either the 75-mg clopidogrel or 5-mg prasugrel dose during Study Period 2 or Study Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in VerifyNow® P2Y12 Reaction Units (PRU) at Day 12 of Therapy</title>
          <description>The Accumetrics VerifyNow® P2Y12 assay measures platelet aggregation in whole blood and is reported in PRU. PRU indicates the extent of P2Y12 receptor-mediated platelet aggregation calculated as a function of rate and extent of platelet aggregation in an adenosine phosphate (ADP)-containing channel of the device. A lower PRU reflects stronger inhibition of platelet aggregation, whereas a higher PRU reflects weaker inhibition of platelet aggregation.</description>
          <population>As-treated pharmacodynamic (PD) population: all randomized participants who received at least 1 dose of study drug and provided at least 1 evaluable PD measure at 1 of the 3 periods. Participants were analyzed based on the treatment they received for each period regardless of their randomized treatment assignment.</population>
          <units>P2Y12 reaction units (PRU)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.9" spread="46.10"/>
                    <measurement group_id="O2" value="315.3" spread="44.26"/>
                    <measurement group_id="O3" value="315.3" spread="44.26"/>
                    <measurement group_id="O4" value="312.8" spread="43.01"/>
                    <measurement group_id="O5" value="311.0" spread="43.76"/>
                    <measurement group_id="O6" value="312.8" spread="43.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12 (n=32,31,32,35,34,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.5" spread="62.14"/>
                    <measurement group_id="O2" value="55.9" spread="38.08"/>
                    <measurement group_id="O3" value="151.7" spread="57.46"/>
                    <measurement group_id="O4" value="193.9" spread="74.09"/>
                    <measurement group_id="O5" value="102.1" spread="69.49"/>
                    <measurement group_id="O6" value="207.0" spread="67.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Analysis of the Concentration-Time Curve (AUC)</title>
        <description>A pharmacokinetic-pharmacodynamic (PK-PD) analysis comparing MPA (LTA) and AUC was conducted as originally intended, however the graphic output is not possible here. Therefore, the PK portion is presented here as AUC and the PD portion is presented in Secondary Outcome Measure #5. AUC was calculated through the last scheduled sampling time of 4 hours [AUC (0-4)] or through the sampling time of the last quantifiable concentration prior to 4 hours. AUC values were denoted AUC(0-tlast) in both instances.</description>
        <time_frame>baseline (pre-dose) up to 4 hours post-dose</time_frame>
        <population>All available PK sample data from all treated participants who contributed complete PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 5 mg (LBW)</title>
            <description>During Study Period 1, participants received the 5-milligram (mg) prasugrel dose for 12 days without intervening or terminal washout periods. Participants in the low body weight (LBW; &lt;60 kilograms [kg]) treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 10 mg (LBW)</title>
            <description>Participants in the LBW treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Clopidogrel 75 mg (LBW)</title>
            <description>Participants in the LBW treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
          </group>
          <group group_id="O4">
            <title>Prasugrel 5 mg (HBW)</title>
            <description>Participants in the higher body weight (HBW; ≥ 60 kg)treatment sequence in Study Period 1 (10 mg prasugrel) were switched to either the 5-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 10 mg (HBW)</title>
            <description>During Study Period 1, participants in the HBW treatment sequence received the 10-mg prasugrel dose for 12 days without intervening or terminal washout periods.</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 75 mg (HBW)</title>
            <description>Participants in the HBW treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Analysis of the Concentration-Time Curve (AUC)</title>
          <description>A pharmacokinetic-pharmacodynamic (PK-PD) analysis comparing MPA (LTA) and AUC was conducted as originally intended, however the graphic output is not possible here. Therefore, the PK portion is presented here as AUC and the PD portion is presented in Secondary Outcome Measure #5. AUC was calculated through the last scheduled sampling time of 4 hours [AUC (0-4)] or through the sampling time of the last quantifiable concentration prior to 4 hours. AUC values were denoted AUC(0-tlast) in both instances.</description>
          <population>All available PK sample data from all treated participants who contributed complete PK profiles.</population>
          <units>nanogram•hour/milliliter (ng•hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Participant Profiles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="37"/>
                    <measurement group_id="O2" value="59.3" spread="40"/>
                    <measurement group_id="O3" value="18.4" spread="38"/>
                    <measurement group_id="O4" value="19.4" spread="46"/>
                    <measurement group_id="O5" value="46.7" spread="44"/>
                    <measurement group_id="O6" value="12.7" spread="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Maximum Platelet Aggregation (MPA) as Measured by Light Transmission Aggregometry (LTA) at Day 12 of Therapy</title>
        <description>MPA to 20 micromolar (μM) adenosine diphosphate (ADP) was assessed by LTA, an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA reflects stronger platelet inhibition, whereas a higher MPA reflects weaker inhibition.</description>
        <time_frame>Baseline , Day 12</time_frame>
        <population>As-treated pharmacodynamic (PD) population: all randomized participants who received at least 1 dose of study drug and provided at least 1 evaluable PD measure at 1 of the 3 periods. Participants were analyzed based on the treatment they received for each period regardless of their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Prasugrel (LBW)</title>
            <description>During Study Period 1, participants received the 5-milligram (mg) prasugrel dose for 12 days without intervening or terminal washout periods. Participants in the low body weight (LBW; &lt;60 kilograms [kg]) treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2.</description>
          </group>
          <group group_id="O2">
            <title>10 mg Prasugrel (LBW)</title>
            <description>Participants in the LBW treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
          </group>
          <group group_id="O3">
            <title>75 mg Clopidogrel (LBW)</title>
            <description>Participants in the LBW treatment sequence in Period 1 (on 5 mg prasugrel) were switched to either the 10-mg prasugrel or the 75-mg clopidogrel dose for Period 2 or Period 3.</description>
          </group>
          <group group_id="O4">
            <title>5 mg Prasugrel (HBW)</title>
            <description>Participants in the higher body weight (HBW; ≥ 60 kg)treatment sequence in Study Period 1 (10 mg prasugrel) were switched to either the 5-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
          </group>
          <group group_id="O5">
            <title>10 mg Prasugrel (HBW)</title>
            <description>During Study Period 1, participants in the (HBW; ≥ 60 kg) treatment sequence received the 10-mg prasugrel dose for 12 days without intervening or terminal washout periods.</description>
          </group>
          <group group_id="O6">
            <title>75 mg Clopidogrel (HBW)</title>
            <description>Participants in the HBW treatment sequence in Study Period 1 (10 mg prasugrel) were switched to either 5-mg prasugrel or the 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maximum Platelet Aggregation (MPA) as Measured by Light Transmission Aggregometry (LTA) at Day 12 of Therapy</title>
          <description>MPA to 20 micromolar (μM) adenosine diphosphate (ADP) was assessed by LTA, an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA reflects stronger platelet inhibition, whereas a higher MPA reflects weaker inhibition.</description>
          <population>As-treated pharmacodynamic (PD) population: all randomized participants who received at least 1 dose of study drug and provided at least 1 evaluable PD measure at 1 of the 3 periods. Participants were analyzed based on the treatment they received for each period regardless of their randomized treatment assignment.</population>
          <units>percent aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.27" spread="9.49"/>
                    <measurement group_id="O2" value="76.20" spread="9.63"/>
                    <measurement group_id="O3" value="76.20" spread="9.63"/>
                    <measurement group_id="O4" value="77.63" spread="12.29"/>
                    <measurement group_id="O5" value="77.93" spread="12.27"/>
                    <measurement group_id="O6" value="77.63" spread="12.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12 ( n= 32,32,31,35,37,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.10" spread="13.89"/>
                    <measurement group_id="O2" value="38.11" spread="14.17"/>
                    <measurement group_id="O3" value="51.41" spread="13.56"/>
                    <measurement group_id="O4" value="61.90" spread="18.93"/>
                    <measurement group_id="O5" value="47.92" spread="15.18"/>
                    <measurement group_id="O6" value="65.28" spread="17.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>5 mg Prasugrel (LBW)</title>
          <description>During Study Period 1, participants received 5 milligrams (mg) prasugrel for 12 days without intervening or terminal washout periods. Participants in the low body weight (LBW; &lt;60 kilograms [kg]) treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2.</description>
        </group>
        <group group_id="E2">
          <title>10 mg Prasugrel (LBW)</title>
          <description>Participants in the LBW treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 10-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
        </group>
        <group group_id="E3">
          <title>75 mg Clopidogrel (LBW)</title>
          <description>Participants in the LBW treatment sequence in Study Period 1 (5 mg prasugrel) were switched to either the 75-mg clopidogrel or 10-mg prasugrel dose during Study Period 2 or Study Period 3.</description>
        </group>
        <group group_id="E4">
          <title>5 mg Prasugrel (HBW)</title>
          <description>Participants in the higher body weight (HBW; ≥ 60 mg) treatment sequence in Study Period 1 (10 mg prasugrel) were switched to either the 5-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
        </group>
        <group group_id="E5">
          <title>10 mg Prasugrel (HBW)</title>
          <description>During Study Period 1, participants in the HBW treatment sequence received the 10-mg prasugrel dose for 12 days without intervening or terminal washout periods.</description>
        </group>
        <group group_id="E6">
          <title>75 mg Clopidogrel (HBW)</title>
          <description>Participants in the HBW treatment sequence in Study Period 1 (10 mg prasugrel) were switched to either the 5-mg prasugrel or 75-mg clopidogrel dose during Study Period 2 or Study Period 3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <description>This event occurred after study completion, but within the 30 day follow-up period. This was the last treatment assigned for this participant.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Macrocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Spontaneous haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Formication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Chronic respiratory disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

